Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-17
2006-10-17
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
07122517
ABSTRACT:
The present invention provides a crystallized NC1 domain hexamer of Type IV collagen, and methods for making the crystal, wherein the NC1 domain hexamer is crystallized such that the three dimensional structure of the crystallized NC1 domain hexamer can be determined to a resolution of at least 3 Å or better. The present invention also provides a method for designing compounds to inhibit angiogenesis, tumor growth, tumor metastasis, endothelial cell adhesion and/or proliferation, and/or basal lamina assembly, comprising analyzing the three dimensional structure of a crystallized Type IV collagen NC1 domain hexamer produced by the methods of the invention, and identifying and synthesizing compounds that target regions of the NC1 domain that have been identified by the analysis as being important for type IV collagen heterotrimer and hexamer assembly. The present invention also provides novel polypeptides designed by the rational drug design methods of the present invention, based on an analysis of the type TV collagen NC1 hexamer structure disclosed herein.
REFERENCES:
patent: 96/00582 (1996-11-01), None
patent: 99/49885 (1999-07-01), None
patent: 00/59532 (2000-12-01), None
patent: 01/51523 (2001-07-01), None
patent: 03/012122 (2003-02-01), None
patent: 04/067762 (2004-08-01), None
Johnson and Tracey, ‘Peptide and Protein Drug Delivery’, In: Encyclopedia of Controlled Drug Delivery, vol. 2, 1999, pp. 816-833.
Maeshima Yohei, et al., (2001) JBC Papers in Press, “Extracellular matrix-derived peptide binds to ανβ3 integrin and inhibits angiogenesis”, pp. 1-39. Aug., 2001.
Maeshima, Yohei, et al., (2001) The Journal of Biological Chemistry, “Identification of the anti-angiogenic site within vascular basement membrane-derived Tumstatin”, vol.: 276(18), pp. 15240-15248.
Appelt, K. (1993)Perspectives in Drug Discovery and Design, “Crystal Structures of HIV-1 Protease Inhibitor Complexes,” 1:23-48.
Bachinger, H.P. et al., (1980)Eur. J. Biochem., “Folding Mechanism of the Triple Helix in Type-III Collagen and Type-III pN-Collagen,” 106:619-632.
Barton, G. J. (1993)Prot. Eng., “ALSCRIPT: A Tool To Format Multiple Sequence Alignments,” 6:37-40.
Blumberg, B. et al., (1988)J. Biol. Chem., “Drosophila Basement Membrane Procollagen α1 (IV),” 263(34):18328-18337.
Borza, D. B. et al. (2001)J Biol. Chem., “The NC1 Domain of Collagen IV Encodes a Novel Network Composed of the α1, α2, α5, and α6 Chanins in Smooth Muscle Basement Membranes,” 276(30):28532-28540.
Boute, N. et al. (1996)Biol. Cell, “Type IV Collagen in Sponges, the Missing Link in Basement Membrane Ubiquity,” 88:37-44.
Boutaud, A. et al., (2000)J. Biol. Chem., “Type IV Collagen of the Glomerular Basement Membrane,” 275:30716-30724.
Brooks, P. C. et al., (1994)Science, “Requirement of Vascular Integrin α1β3for Angiogenesis,” 264:569-571.
Brooks. P. C. et al., (1997)J. Clin. Invest., “Insulin-like Growth Factor Receptor Cooperates With Integrin ανβ5 to Promote Tumor Cell Dissemination in Vivo,” 99:1390-1398.
Brooks, P. C. et al., (1998)Cell, “Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity,” 92:391-400.
Colorado, et al., (2000) Cancer Research, “Anti-Angiogenic Cues from Vascular Basement Membrane Collagen”, vol.: 60, pp. 2520-2526.
Cosgrove, D. et al., (1996)Genes&Dev., “Collagen COL4A3 Knockout: A Mouse Model for Autosomal Alport Sundrome,” 10(23):2981-92.
Dion, A. S., and Myers, J. C. (1987)J Mol. Biol., “COOH-terminal Propeptides of the Major Human Procollagens Structural, Functional and Genetic Comparisons,” 193(1):127-43.
Dolz, R. et al., (1988)Eur J Biochem., “Folding of Collagen IV,” 178(2), 357-66.
Dvorak, H. F. et al., (1987)Lab. Invest., “Fibrin Containing Gels Induce Angiogenesis,” 57:673-686.
Exposito, J. Y. et al., (1993)J Biol Chem., “Complete Primary Structure of a Sea Urchin Type IV Collagen α Chain and Analysis of the 5'End of Its Gene,” 268(7):5249-54.
Fawzi, A., et al., (2000), “Cellular Signal, A Peptide of the α3(IV) Chain of Type IV Collagen Modulates Stimulated Neutrophil Function Via Activation of cAMP-dependent Protein Kinase and Ser/Thr Protein Phosphatase,” 12:327-335.
Folkman, J. (1985)Perspect, Biol. Med., “Toward an Understanding of Angiogenesis: Search and Discovery,” 29:10-36.
Fowler, S. J., et al., (2000)J Biol Chem., “Characterization of Hydra Type IV Collagen,” 275(50):39589-99.
Gunwar, S., et al., (1998)J. Biol. Chem., “Glomerular Basement Membrane,” 273(15):8767-8775.
Gunwar, S. et al., (1991)J. Biol. Chem., “Properties of the Collagenous Domain of the α3(IV) Chain, the Goodpastuyre Antigen, of Lens Basement Membrane Collagen,” 266(21):14088-94.
Guo, X. D., and Kramer, J. M. (1989)J. Biol. Chem., “The TwoCaenorhabditis ElegansBasement Membrane (Type IV) Collagen Genes Are Located on Separate Chromosomes,” 264(29):17574-82.
Guo, X. et al., (1991)Nature, “Embryonic Lethality Caused By Mutations In Basement Membrane Collagen of C.elegans” 349:707-709.
Han, J. et al., (1997)Journal of Biological Chemistry, “A Cell Binding Domain from the α3 Chain of Type IV Collagen Inhibits Proliferation of Melanoma Cells,” 272:20395-20401.
Hellmark, et al., (1996), Clin Exp Immunol, Epitope Mapping of anti-glomerular basement membrane (GBM) antibodies with synthetic peptides, vol.: 105: pp. 504-510.
Hohenester, E. et al., (1998)EMBO J., “Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution,” 17:1656-1664.
Hudson, B. G. et al., (1993)J. Biol. Chem., “Type IV Collagen: Structure, Gen Organization, and Role in Human Diseases,” 268(35):26033-6.
Kashtan, C. E., and Michael, A. F. (1993)Am. J. Kid. Dis., “Alport Syndrome: From Bedside to Genome to Bedside,” 22:627-640.
Kashtan, C. E., and Michael, A. F. (1996)Kidney Int., “Alport Syndrome: Perspectives in Clinical Nephrology,” 50:1445-1463.
Kefalides, N. A. et al. (1999)Medicina, “Suppression of Tumor Cell Growth by Type IV Collagen and a Peptide from the NCI Domain of the α3 (IV) Chain,” 59:553.
Koliakos, et al., (1989), The Journal of Biological Chemistry, “The Binding of Heparin to Type IV Collagen: Domain Specificity with Identification of Peptide Sequences from the alpha 1 (IV) and alpha2 (IV) which preferentially bind heparin”, vol.: 264(4), pp. 2313-2323.
Lam, P. Y. S. et al., (1994)Science, “Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors,” 263:380-384.
Langeveld, J. P. M. et al., (1988)J. Biol. Chem., “Structural Heterogeneity of the Noncollagenous Domain of Basement Membrane Collagen,” 263(21):10481-8.
Laskowski, R. A. (1995)J. Mol. Graph., “SURFNET: A Program for Visualization Molecular Surfaces, Cavities, and Intermolecular Interactions,” 13:323-330.
Laskowski, R. A. et al., (1993)J. Appl. Cryst., “PROCHECK: A Program to Check the Sterochemical Quality of Protein Structures,” 26:283-291.
Lees, J. F. et al., (1997)EMBO J., “Identification of the Molecular Recognition Sequence Which Determines the Type-specific Assembly of Procollagen,” 16(5):908-916.
Luo, A. M. et al., (2002), J. Lab Clin. Med., “Synthetic Peptides of Goodpasture's Antigen In Antiglomerular Basement Membrane Nephritis in Rats,” 139(5): 303-310.
Marneros, A.G., and Olsen, B. R. (2001), “Matrix Biol., The Role of Collagen-Derived Proteolytic Fragments in Angiogenesis,” 20:337-345.
Maeshima, et al., (2001), The Journal of Biological Chemistry, “Extracellular Matrix-derived Peptide Binds t
Hudson Billy G.
Sundaramoorthy Munirathinam
Canella Karen A.
Kansas University Medical Center
McDonnell Boehnen & Hulbert & Berghoff LLP
LandOfFree
Crystallized structure of type IV collagen NC1 domain hexamer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystallized structure of type IV collagen NC1 domain hexamer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystallized structure of type IV collagen NC1 domain hexamer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3641094